Target intelligence / Profile preview

Bifunctional apoptosis regulator (BFAR)

Target
BFAR
Molecular classification
E3 ubiquitin ligase, RING finger protein, Endoplasmic reticulum-associated protein, Other (apoptosis regulator)
01

Overview

Bifunctional apoptosis regulator (BFAR) is a membrane-bound, endoplasmic reticulum-associated E3 ubiquitin ligase containing a RING finger domain and additional regulatory domains[1][3][4]. It exerts anti-apoptotic functions by inhibiting apoptotic pathways activated by both mitochondrial factors and death receptors[3][5]. BFAR promotes ubiquitination and degradation of specific substrate proteins such as PNPLA3—a factor implicated in lipid metabolism and fatty liver disease[1]—and the Bax inhibitor-1 (BI-1), thereby modulating responses to ER stress and unfolded protein response signaling[3][4]. It is highly expressed in neuronal tissues and protects neurons against a broad range of apoptotic stimuli[5]. BFAR's activity links it to disease roles in cancer, neurodegeneration, and metabolic conditions, but it is not currently a direct target for any approved therapeutic drugs[3][5].

Other names
BFARBARRNF47RING finger protein 47bifunctional apoptosis inhibitor
02

Mechanism of action

Enhancement or inhibition of ubiquitin ligase activity to regulate substrate degradation Modulation of apoptosis through negative regulation (anti-apoptotic role) Regulation of ER stress responses and unfolded protein response signaling

03

Biological functions

Negative regulation of apoptosis (anti-apoptotic activity)[3][5]Ubiquitination of proteins (promotes proteasome-mediated protein degradation)[1][3][4]Regulation of unfolded protein response and ER stress[3][4]Negative regulation of IRE1-mediated signaling (UPR)[3][4]Protein-macromolecule adaptor activity[3]
04

Disease associations

Cancer (implicated in cell survival and anti-apoptotic effects)[2]Neurodegenerative disease (protects neurons from apoptosis)[5]Lipid metabolism disorders (involved in regulation of PNPLA3 in fatty liver disease)[1]Other (ER stress-related diseases)
05

Safety considerations

Potential challenges include broad involvement in apoptosis and protein homeostasis; its inhibition may cause unintended toxicity due to disruption of cell survival pathways[3][4][5]Lack of specificity in targeting, as ubiquitin ligases act on multiple substrates, could increase the risk of off-target effects if therapeutically modulated[3][4]

Beyond the preview

Go deeper on Bifunctional apoptosis regulator (BFAR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifunctional apoptosis regulator (BFAR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call